Coronary Intervention & Surgery

Oregon Health & Science University Hospital saw an “alarming” number of patient deaths in 2017, the year before its heart transplant program ultimately crumbled, new data has revealed.

Spontaneous coronary artery dissection is emerging from the shadows as an important cause of myocardial infarction in younger women. That visibility is leading to fundamental changes in how the condition is diagnosed and treated.

A miniscule fiber-optic sensor could outperform more traditional methods for monitoring blood flow during prolonged and intensive surgical CV procedures, even in the smallest and youngest heart patients, researchers at Flinders University in Australia report.

The cardiovascular stents market is expected to reach $13.1 billion by 2025, up from $7.8 billion in 2017, according to projections from Fortune Business Insights.

North Carolina Children’s Hospital will be suspending heart surgeries for its most complex cases for the time being—a direct response to a New York Times investigation that called into question the safety of practices in the center’s pediatric heart surgery unit—the Times reported June 17.

Mount Sinai Heart announced June 10 that a pair of its top cardiothoracic surgeons succeeded in performing two totally endoscopic coronary arterial bypass surgeries (TECABs) at the end of May, making the hospital the only center in New York State qualified to offer the procedure.

Ultrathin drug-eluting stents performed better than their thicker counterparts in a recent analysis of the BIO-RESORT trial, researchers reported in JAMA Cardiology May 21—but thinner struts might not always be the right go-to for patients after PCI.

Corindus Vascular Robotics’ CorPath GRX system—the world’s only FDA-approved and CE-marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention—was used in the first-ever live transmission of a robotic PCI in Europe during this year's EuroPCR congress.

Three-year results of the BIO-RESORT study, presented at EuroPCR this week in Paris, put Biotronik’s ultrathin Orsiro stent ahead of two other competitors in terms of target lesion failure and revascularization.

The bioresorbable vascular scaffold, once an exciting prospect for cardiologists, saw a unique rise and fall in popularity within a year of its introduction to the CV market.

Atrial fibrillation patients with coronary artery disease pose a delicate balancing act for physicians. A growing awareness of bleeding vs. ischemic risks could soon lead to a steadier therapeutic response.

Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.